Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most high-level treatment rationale (BH4/Phe reduction, responsive PKU, need for diet, and blood Phe monitoring/discontinuation for lack of response) aligns with label themes, but several mechanistic and risk/benefit claims are not supported by the supplied prescribing information, and some adverse-effects/monitoring statements are overstated or not label-anchored.
Category Scores
Accurate Statements
Sapropterin is used to treat phenylketonuria (PKU).
Indications and Usage: JAVYGTOR indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia due to tetrahydrobiopterin-(BH4-responsive) PKU (Section 1).
Sapropterin works by replenishing the body's stores of BH4.
Drug interactions section states inhibitors of folate synthesis may decrease net BH4; suggests sapropterin relates to BH4 availability (Section 7). (Mechanistic detail is only partially supported by supplied text.)
BH4 is a critical cofactor for the enzyme phenylalanine hydroxylase (PAH).
No explicit statement in the provided label text regarding PAH as a BH4 cofactor.
PAH converts Phe into tyrosine.
No explicit statement in the provided label text.
In PKU patients, the PAH enzyme is either deficient or non-functional.
No explicit statement in the provided label text.
By increasing BH4 levels, sapropterin helps restore PAH activity.
Not explicitly stated in supplied label text.
Reducing Phe levels alleviates symptoms associated with PKU.
Label emphasizes reducing blood Phe levels and preventing severe neurologic damage but does not explicitly link reduced Phe levels to symptom alleviation in the supplied text.
The goal of PKU treatment is to maintain Phe levels within a target range to prevent neurological damage and other complications.
Warnings and Precautions: prolonged elevations of blood Phe can result in severe neurologic damage; active management and monitoring are required (Section 5.4). Target-range language not explicitly provided.
Individual responses to sapropterin can vary greatly.
Warnings and Precautions: lack of biochemical response; some patients do not show biochemical response (Section 5.5).
If blood Phe does not decrease from baseline at 10 mg/kg per day, the dose may be increased to 20 mg/kg per day.
Dosage and Administration (2.2): if 10 mg/kg starting dose used and blood Phe does not decrease after up to 1 month, dose may be increased to 20 mg/kg per day.
If blood Phe does not decrease after 1 month of treatment at 20 mg/kg per day, treatment with JAVYGTOR should be discontinued in these patients.
Dosage and Administration (2.2): discontinue in patients without biochemical response after 1 month at 20 mg/kg per day.
Blood Phe levels should be checked after 1 week of JAVYGTOR treatment and periodically for up to a month.
Dosage and Administration (2.2): blood Phe checked after 1 week and periodically during the first month.
Patients should be closely monitored by a healthcare provider when taking higher dosages of sapropterin dihydrochloride.
Label recommends blood Phe monitoring during treatment; pediatric frequent blood monitoring is recommended (Section 5.4) and monitoring during evaluation period (Section 2.2). (“Higher dosages” specifically not stated but increased monitoring with dose adjustment is consistent with provided text.)
Unsupported Statements
PKU is a genetic disorder that affects the body's ability to break down phenylalanine (Phe).
No such characterization is explicitly provided in the supplied label text.
PKU can lead to severe neurological damage and other complications if left untreated.
The label states prolonged elevations of blood Phe can result in severe neurologic damage, but does not explicitly say 'if left untreated' or 'other complications' in the provided text.
BH4 is a critical cofactor for the enzyme phenylalanine hydroxylase (PAH).
Mechanistic cofactor relationship is not stated in the provided label excerpts.
PAH converts Phe into tyrosine.
Not stated in the provided label excerpts.
In PKU patients, the PAH enzyme is either deficient or non-functional.
Not stated in the provided label excerpts.
PKU causes accumulation of Phe in the body.
The label uses 'reduce blood Phe levels' and discusses blood Phe control, but does not explicitly state this mechanism as a cause.
By increasing BH4 levels, sapropterin helps restore PAH activity.
Not stated in the provided label excerpts.
Restoring PAH activity reduces Phe levels.
Not stated in the provided label excerpts.
The standard treatment for PKU involves dietary restrictions and sapropterin supplementation.
Label states JAVYGTOR is to be used in conjunction with a Phe-restricted diet, but does not call this the 'standard treatment' for PKU.
Some patients may require higher dosages of sapropterin to achieve optimal symptom relief.
Label describes dose adjustment based on biochemical response (blood Phe), not 'symptom relief'.
Higher sapropterin dosages may be associated with improved symptom relief in PKU patients.
Label focuses on blood Phe changes and biochemical response; symptom-relief framing is not supported by supplied text.
A study reported that patients receiving higher doses of sapropterin (up to 20 mg/kg/day) experienced significant reductions in Phe levels compared with those receiving lower doses (1-10 mg/kg/day).
No quantitative cross-dose study result is included in the provided label excerpts.
A study reported that patients receiving higher doses of sapropterin (up to 20 mg/kg/day) had improvements in cognitive function compared with those receiving lower doses (1-10 mg/kg/day).
No cognitive function outcomes are presented in the supplied label excerpts.
Higher sapropterin dosages lead to increased BH4 levels.
No statement in the supplied label text explicitly links higher doses to increased BH4 levels.
Increased BH4 levels enhance PAH activity and reduce Phe levels.
Label does not state this mechanistic chain in the provided excerpts.
Higher BH4 levels may stabilize the PAH enzyme.
Not stated in provided label excerpts.
Stabilizing the PAH enzyme reduces its degradation and increases its activity.
Not stated in provided label excerpts.
BH4 plays a critical role in mitochondrial function.
Not stated in provided label excerpts.
Higher sapropterin dosages may improve mitochondrial function in PKU patients.
Not stated in provided label excerpts.
Higher sapropterin dosages may be beneficial for patients with severe PKU.
No 'severe PKU' subgroup-based benefit statement is included in provided excerpts.
Higher sapropterin dosages may be beneficial for patients with poor dietary compliance.
Label emphasizes active management of dietary Phe intake while taking JAVYGTOR, but does not state dose escalation benefits poor dietary compliance.
Higher sapropterin dosages may help maintain Phe levels within target ranges in patients with poor dietary compliance.
Label provides monitoring/active management but does not support this conditional statement.
Higher sapropterin dosages may be beneficial for patients who experience adverse effects from standard sapropterin dosages.
Label does not state dose increases as a remedy for adverse effects.
Higher sapropterin dosages are associated with adverse effects such as nausea and vomiting.
The supplied label text lists vomiting as a common adverse reaction, but does not link adverse effects to higher doses.
Patients should be closely monitored by a healthcare provider when taking higher dosages of sapropterin dihydrochloride.
Label supports blood Phe monitoring during dose evaluation/adjustment, but 'closely monitored when taking higher dosages' is not explicitly stated as such in provided excerpts.
Contradictions
Important Omissions
No mention that JAVYGTOR is indicated specifically for hyperphenylalaninemia due to BH4-responsive PKU, and is to be used in conjunction with a Phe-restricted diet (key qualifying indication and required concomitant therapy).
Importance:
Moderate
No mention of contraindications (None) and key warnings relevant to safe use: hypersensitivity/anaphylaxis, GI mucosal inflammation/esophagitis/gastritis, hypophenylalaninemia (low blood Phe), and levodopa interaction monitoring.
Importance:
Moderate
No clear dosing instructions (starting 10 mg/kg for ages 1 month–6 years; 10–20 mg/kg for age 7+; administer with a meal; missed dose instruction; preparation volumes/packet guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several mechanistic and dose-response benefit claims are not supported by the supplied label excerpts. The most safety-relevant label-supported elements (blood Phe monitoring, risk of low Phe, hypersensitivity/GI inflammation) are not addressed. Overstated causal links (e.g., cognition/mitochondria, higher-dose adverse-effect association) could mislead users about expectations and safety monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many statements are mechanistic or dose-response claims not supported by the provided prescribing information, and key label safety/administration details are omitted.
Suggested Improvement
Restrict claims to label-supported points: indication (BH4-responsive PKU/HPA), required Phe-restricted diet use, dosing and evaluation period with blood Phe monitoring schedule, discontinuation for lack of biochemical response, and label warnings (hypersensitivity/anaphylaxis, upper GI mucosal inflammation, hypophenylalaninemia, levodopa interaction).